A Multi-Center Retrospective Study to Describe Clinical Characteristics and Outcomes of Early EVENITY Users, Transitioning to Antiresorptive Agents in Japa
Not Applicable
- Conditions
- osteoporosis
- Registration Number
- JPRN-UMIN000042554
- Lead Sponsor
- Amgen K.K. Medical Affairs Japan
- Brief Summary
There was a total of 1027 patients in this study of which >=90% were female. The mean age at the initiation of EVENITY for all patients was 77.0 years. A percentage of 54.9% of patients had previous OP medications within 6 months before EVENITY initiation. At 12 and 18 months of treatment, the mean percent change in BMD from baseline was 13.4% and 13.8% for the LS, 4.0% and 4.8% for TH, and 3.6% and 4.5% for FN in the FAS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1027
Inclusion Criteria
Not provided
Exclusion Criteria
Conditions specified as contraindication in Japanese package insert: - Patients with a history of hypersensitivity to any of the ingredients of EVENITY - Patients with hypocalcemia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method